


**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A compound represented by the formula (I):



wherein  $R^7$  and  $R^{21}$  [[,]] are the same or are different [[,]] and represent

- 1) a  $C_2$  to  $C_{22}$  alkoxy group which may have a substituent,
- 2) an unsaturated  $C_2$  to  $C_{22}$  alkoxy group which may have a substituent,
- 3) a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5)  $RC(=Y)-O-$ , wherein Y represents an oxygen atom or sulfur atom, and R represents
  - a) a hydrogen atom,
  - b) a  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,
  - c) an unsaturated  $C_2$  to  $C_{22}$  alkyl group which may have a substituent,
  - d) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent, or
  - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
  - f) a  $C_7$  to  $C_{22}$  aralkyl group which may have a substituent,
  - g) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

- h) a C<sub>1</sub> to C<sub>22</sub> alkoxy group which may have a substituent,
- i) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent,
- j) a C<sub>6</sub> to C<sub>14</sub> aryloxy group which may have a substituent, or
- k) a C<sub>3</sub> to C<sub>14</sub> cycloalkyl group which may have a substituent,
- l) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
- m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

6) R<sup>S1</sup>R<sup>S2</sup>R<sup>S3</sup>SiO, wherein R<sup>S1</sup>, R<sup>S2</sup> and R<sup>S3</sup>, the same or different, represent

- a) a C<sub>1</sub> to C<sub>6</sub> alkyl group or
- b) a C<sub>6</sub> to C<sub>14</sub> aryl group,

7) a halogen atom,

[[ 8) ]] R<sup>N1</sup>R<sup>N2</sup>N-R<sup>M</sup>-, wherein R<sup>M</sup> represents

- a) a single bond,
- b) -CO-O-,
- c) SO<sub>2</sub>O-,

[[ d) ]] c) -CS-O- or

[[ e) ]] d) -CO-NR<sup>N3</sup>-, wherein R<sup>N3</sup> represents a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and

wherein R<sup>N1</sup> and R<sup>N2</sup> [[,]] are the same or are different [[,]] and represent

- a) a hydrogen atom,
- b) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent,
- c) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent,
- d) an aliphatic C<sub>2</sub> to C<sub>22</sub> acyl group which may have a substituent,
- e) an aromatic C<sub>7</sub> to C<sub>15</sub> acyl group which may have a substituent,
- f) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- h) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent,
- i) a C<sub>1</sub> to C<sub>22</sub> alkylsulfonyl group which may have a substituent,
- j) a C<sub>6</sub> to C<sub>14</sub> arylsulfonyl group which may have a substituent,
- k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>N1</sup> and R<sup>N2</sup> together in combination with the nitrogen atom to which R<sup>N1</sup> and R<sup>N2</sup> are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- m) a C<sub>3</sub> to C<sub>14</sub> cycloalkyl group which may have a substituent or
- n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent [.,.]

9) R<sup>N4</sup>SO<sub>2</sub>—O—, wherein R<sup>N4</sup> represents

- a) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent,
- b) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- c) a C<sub>1</sub> to C<sub>22</sub> alkoxy group which may have a substituent,

- d) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent;
- e) a C<sub>6</sub> to C<sub>14</sub> aryloxy group which may have a substituent;
- f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent;
- g) a C<sub>7</sub> to C<sub>22</sub> aralkyloxy group which may have a substituent or
- h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent;

10)  $(R^{N5}O)_2PO-O$ , wherein R<sup>N5</sup> represents

- a) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent;
- b) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent;
- c) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent;
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent;
- e) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent or
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent;

11)  $(R^{N1}R^{N2}N)_2PO-O$ , wherein R<sup>N1</sup> and R<sup>N2</sup> are the same as defined above or


12)  $(R^{N1}R^{N2}N)(R^{N5}O)PO-O$ , wherein R<sup>N1</sup>, R<sup>N2</sup> and R<sup>N5</sup> are the same as defined above; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:

C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group,

piperadyl group, piperidyl group and pyridyl group.

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):



wherein R<sup>7a</sup> and R<sup>21a</sup> [,,] are the same or are different [,,] and represent

- 1) a C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent;
- 2) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent;
- 3) a C<sub>7</sub> to C<sub>22</sub> aralkyloxy group which may have a substituent;
- 4) R<sup>a</sup>C(=Y<sup>a</sup>)-O-, wherein Y<sup>a</sup> represents an oxygen atom or sulfur atom, and R<sup>a</sup> represents
  - a) a hydrogen atom;
  - b) a C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent;
  - c) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent;
  - d) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent, or
  - e) a 5-membered to 14-membered heteroaryl group which may have a substituent;
  - f) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent;
  - g) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

- h) a C<sub>1</sub> to C<sub>22</sub> alkoxy group which may have a substituent;
- i) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkoxy group which may have a substituent;
- j) a C<sub>6</sub> to C<sub>14</sub> aryloxy group which may have a substituent, or
- k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent;

[[5]]] R<sup>aN1</sup>R<sup>aN2</sup>N-CO-O-, wherein R<sup>aN1</sup> and R<sup>aN2</sup>, the same or different, represent

- a) a hydrogen atom,
- b) a C<sub>1</sub> to C<sub>22</sub> alkyl group which may have a substituent,
- c) an unsaturated C<sub>2</sub> to C<sub>22</sub> alkyl group which may have a substituent,
- d) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- f) a C<sub>7</sub> to C<sub>22</sub> aralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>aN1</sup> and R<sup>aN2</sup> together in combination with the nitrogen atom to which R<sup>aN1</sup> and R<sup>aN2</sup> are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
- h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- i) a C<sub>3</sub> to C<sub>14</sub> cycloalkyl group which may have a substituent or
- j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, or

6)  $\text{R}^{\text{aN1}}\text{R}^{\text{aN2}}\text{N}-\text{SO}_2-\text{O}$ , wherein  $\text{R}^{\text{aN1}}$  and  $\text{R}^{\text{aN2}}$  are the same as defined above,

[[7]]]  $\text{R}^{\text{aN1}}\text{R}^{\text{aN2}}\text{N}-\text{CS}-\text{O}$ , wherein  $\text{R}^{\text{aN1}}$  and  $\text{R}^{\text{aN2}}$  are the same as defined above,

8)  $\text{RaN4SO}_2\text{O}$ , wherein  $\text{RaN4}$  represents

- a) a C1 to C22 alkyl group which may have a substituent,
- b) a C6 to C14 aryl group which may have a substituent,
- c) a C1 to C22 alkoxy group which may have a substituent,
- d) an unsaturated C2 to C22 alkoxy group which may have a substituent,
- e) a C6 to C14 aryloxy group which may have a substituent,
- f) a 5 membered to 14 membered heteroaryloxy group which may have a substituent,
- g) a C7 to C22 aralkyloxy group which may have a substituent or
- h) a 5 membered to 14 membered heteroaralkyloxy group which may have a substituent,

9)  $(\text{R}^{\text{aNs}}\text{O})_2\text{PO}-\text{O}$ , wherein  $\text{R}^{\text{aNs}}$  represents

- a) a C1 to C22 alkyl group which may have a substituent,
- b) an unsaturated C2 to C22 alkyl group which may have a substituent,
- c) a C6 to C14 aryl group which may have a substituent,
- d) a 5 membered to 14 membered heteroaryl group which may have a substituent,
- e) a C7 to C22 aralkyl group which may have a substituent or
- f) a 5 membered to 14 membered heteroaralkyl group which may have a substituent,

10)  $(\text{R}^{\text{aN1}}\text{R}^{\text{aN2}}\text{N})_2\text{PO}-\text{O}$ , wherein  $\text{R}^{\text{aN1}}$  and  $\text{R}^{\text{aN2}}$  are the same as defined above or

11)  $(R^{N1}R^{N2}N)(R^{N5}O)PO-O$ , wherein  $R^{N1}$ ,  $R^{N2}$  and  $R^{N5}$  are the same as defined above; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:  $C_1-C_6$  alkyl group, phenyl group, halogen, hydroxyl group,  $C_1-C_6$  alkoxy group, thiol group,  $C_1-C_6$  alkylthio group, nitro group, nitroso group, cyano group,  $C_1-C_6$  alkoxy carbonyl group, amino group, mono ( $C_1-C_6$  alkyl) amino group, di ( $C_1-C_6$  alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

3. (Currently Amended) The compound according to claim 1, wherein  $R^7$  and/or  $R^{21}$  represent a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent,  $RC(=Y)-O-$ , wherein Y and R are the same as defined above, or  $R^{N1}R^{N2}N-R^M-$ , wherein  $R^M$  represents


a) -CO-O- or

b) -CS-O-, and  $R^{N1}$  and  $R^{N2}$  are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:  $C_1-C_6$  alkyl group, phenyl group, halogen, hydroxyl group,  $C_1-C_6$  alkoxy group, thiol group,  $C_1-C_6$  alkylthio group, nitro group, nitroso group, cyano group,  $C_1-C_6$  alkoxy carbonyl group, amino group, mono ( $C_1-C_6$  alkyl) amino group, di ( $C_1-C_6$  alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.


4. (Currently Amended) The compound according to claim 1, wherein  $R^{N1}$  and  $R^{N2}$  [[,]] are the same or are different [[,]] and represent a  $C_1$  to  $C_6$  alkyl group or  $C_6$  to  $C_{14}$  aryl group, or

form, together in combination with the nitrogen atom to which  $R^{N1}$  and  $R^{N2}$  are bonded, a non-aromatic heterocyclic group selected from the group consisting of:



or a pharmacologically acceptable salt thereof.


5. (Currently Amended) The compound according to claim 2 represented by the formula (I-b):



wherein  $R^{7b}$  and  $R^{21b}$  ~~[[,]]~~ are the same or ~~are~~ different ~~[[,]]~~ and represent a  $C_7$  to  $C_{22}$  aralkyloxy group which may have a substituent, or  $R^b-C(=Y^b)-O-$ , wherein  $Y^b$  represents an oxygen atom or sulfur atom, and  $R^b$ , the same or different, represents

- a) a hydrogen atom;
- b) a  $C_2$  to  $C_6$  alkyl group which may have a substituent;

[[c]] a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent, or  
d) a 5 membered to 14 membered heteroaryl group which may have a substituent,  
e) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,  
f) a 5 membered to 14 membered heteroaralkyl group which may have a substituent,  
g) a 3 membered to 14 membered non aromatic heterocyclic group which may have a substituent,  
h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X<sub>b</sub> represents

- i) -CHR<sup>bN4</sup>-,
- ii) -NR<sup>bN5</sup>-,
- iii) -O-,
- iv) -S-,
- v) -SO- or
- vi) -SO<sub>2</sub>-,

R<sup>bN1</sup> represents

- i) a hydrogen atom or
- ii) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

$R^{bN2}$  represents

- i) a hydrogen atom or
- ii) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

$R^{bN3}$  and  $R^{bN4}$ , the same or different, represent

- i) a hydrogen atom,
- ii) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- iii) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- iv) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- vii) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- viii) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) -NR<sup>bN6</sup>R<sup>bN7</sup>, wherein R<sup>bN6</sup> and R<sup>bN7</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bN3</sup> and R<sup>bN4</sup> together in combination with the carbon atom to which R<sup>bN3</sup> and R<sup>bN4</sup> are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

$R^{bN5}$  represents

- i) a hydrogen atom,
- ii) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- iii) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- iv) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- vii) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- viii) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or
- xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bN3</sup> and R<sup>bN5</sup> together in combination with the nitrogen atom to which R<sup>bN3</sup> and R<sup>bN5</sup> are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X<sub>b</sub>, n, R<sup>bN3</sup>, R<sup>bN4</sup> and R<sup>bN5</sup> represent the same group as defined above, and R<sup>bN1</sup> and R<sup>bN2</sup> represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>bN1</sup> and R<sup>bN2</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

C)


X<sub>b</sub>, n, R<sup>bN2</sup>, R<sup>bN4</sup> and R<sup>bNn5</sup> represent the same group as defined above, and R<sup>bN1</sup> and R<sup>bN3</sup>

represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{bN1}$  and  $R^{bN3}$  together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

$X_b$ ,  $n$ ,  $R^{bN1}$ ,  $R^{bN4}$  and  $R^{bN5}$  represent the same group as defined above, and  $R^{bN2}$  and  $R^{bN3}$  represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by  $R^{bN2}$  and  $R^{bN3}$  together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein  $R^{bN8}$  and  $R^{bN9}$ , the same or different, represent

- i) a hydrogen atom,
- ii) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,
- iii) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- v) a  $C_7$  to  $C_{10}$  aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:


C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

6. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a1</sup>C(=Y<sup>a1</sup>)-O-, wherein Y<sup>a1</sup> represents an oxygen atom or sulfur atom, and R<sup>a1</sup> represents

- [[1]] a hydrogen atom, or
- 2) a C<sub>2</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>6</sub> to C<sub>10</sub> aryl group which may have a substituent,
- 4) a 5 membered to 14 membered heteroaryl group which may have a substituent,
- 5) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent or
- 6) a 5 membered to 14 membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of: C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

7. (Currently Amended) The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a2}C(=Y^{a2})-O-$ , wherein  $Y^{a2}$  represents an oxygen atom or ~~sulfur atom~~, and  $R^{a2}$  represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,

$X_1$  represents

- 1)  $-CHR^{aN9}-$ ,
- 2)  $-NR^{aN10}-$ ,
- 3)  $-O-$ ,
- 4)  $-S-$ ,
- 5)  $-SO-$  or
- 6)  $-SO_2-$ ,

$R^{aN6}$  and  $R^{aN7}$ , the same or different, represent

- 1) a hydrogen atom or
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,

$R^{aN8}$  and  $R^{aN9}$ , the same or different, represent

- 1) a hydrogen atom,
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,
- 3) an unsaturated  $C_2$  to  $C_{10}$  alkyl group which may have a substituent,


- 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) -NR<sup>aN11</sup>R<sup>aN12</sup>, wherein R<sup>aN11</sup> and R<sup>aN12</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>aN8</sup> and R<sup>aN9</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and  
R<sup>aN10</sup> represents
  - 1) a hydrogen atom,
  - 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
  - 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
  - 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
  - 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
  - 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
  - 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R<sup>aN10</sup> is bonded, and one substituent selected from the group consisting of R<sup>aN6</sup>, R<sup>aN7</sup> and R<sup>aN8</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R<sup>aN10</sup> is bonded, and two substituents selected from the group consisting of R<sup>aN6</sup>, R<sup>aN7</sup> and R<sup>aN8</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

B) n, X<sub>1</sub>, R<sup>aN7</sup>, R<sup>aN9</sup> and R<sup>aN10</sup> represent the same group as defined above, and R<sup>aN6</sup> and R<sup>aN8</sup> represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R<sup>aN6</sup> and R<sup>aN8</sup> together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof.

8. (Previously Presented) The compound according to claim 7, wherein X<sub>1</sub> represents -NR<sup>aN10</sup>-, wherein NR<sup>aN10</sup> is the same as defined above; or a pharmacologically acceptable salt thereof.

9. (Currently Amended) The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a3}C(=Y^{a3})-O-$ , wherein  $Y^{a3}$  represents an oxygen atom or sulfur atom, and  $R^{a3}$  represents a group of the formula (V):



wherein  $n$  represents an integer of 0 to 4,

$R^{aN13}$  represents

- 1) a hydrogen atom or
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent, and


$R^{aN14}$  represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridinyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,
- 6) a morpholin-4-yl group which may have a substituent or
- 7) a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof,

wherein said substituents are each independently selected from the group consisting of:  
 $C_1-C_6$  alkyl group, phenyl group, halogen, hydroxyl group,  $C_1-C_6$  alkoxy group, thiol group,  $C_1-$

C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

10. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a4</sup>CO-O-, wherein R<sup>a4</sup> represents a group of the formula (VI):



wherein n<sub>1</sub> and n<sub>2</sub> [[,]] are the same or are different [[,]] and represent an integer of 0 to 4,  
X<sub>2</sub> represents

- 1) -CHR<sup>aN17</sup>-,
- 2) -NR<sup>aN18</sup>-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO<sub>2</sub>-,

R<sup>aN15</sup> represents

- 1) a hydrogen atom or
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

R<sup>aN16</sup> represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent or
- 4) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

R<sup>aN17</sup> represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) -NR<sup>aN19</sup>R<sup>aN20</sup>, wherein R<sup>aN19</sup> and R<sup>aN20</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or
- 11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R<sup>aN18</sup> represents


- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,

- 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:

C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

11. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a5</sup>CO-O-, wherein R<sup>a5</sup> represents a group of the formula (VII):



wherein n<sub>3</sub> represents 1 or 2,

R<sup>aN21</sup> represents

- 1) a hydrogen atom or
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent, and


R<sup>aN22</sup> represents

- 1) a hydrogen atom or
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:

C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

12. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a6</sup>CO-O-, wherein R<sup>a6</sup> represents a group of the formula (VIII):



wherein n<sub>1</sub> and n<sub>2</sub> [[,]] are the same or are different [[,]] and represent an integer of 0 to 4,  
X<sub>3</sub> represents

- 1) -CHR<sup>aN25</sup>-,

2) -NR<sup>aN26</sup>-,

3) -O-,

4) -S-,

5) -SO- or

6) -SO<sub>2</sub>-,

R<sup>aN23</sup> represents

1) a hydrogen atom or

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

R<sup>aN24</sup> represents

1) a hydrogen atom,

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent or

4) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

R<sup>aN25</sup> represents

1) a hydrogen atom,

2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,

3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,

4) a C<sub>1</sub> to C<sub>6</sub> alkoxy group which may have a substituent,

5) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,

6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,

8) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,

- 9) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 11) -NR<sup>aN27</sup>R<sup>aN28</sup>, wherein R<sup>aN27</sup> and R<sup>aN28</sup>, the same or different, represent a hydrogen atom or a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent or
- 12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R<sup>aN26</sup> represents


- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) an unsaturated C<sub>2</sub> to C<sub>10</sub> alkyl group which may have a substituent,
- 4) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:  
C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino

group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

13. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a7</sup>CO-O-, wherein R<sup>a7</sup> represents a group of the formula (IX):



wherein n<sub>4</sub> represents an integer of 1 to 3, and


R<sup>aN29</sup> represents

- 1) an amino group which may have a substituent,
- 2) a pyrrolidin-1-yl group which may have a substituent,
- 3) a piperidin-1-yl group which may have a substituent or
- 4) a morpholin-4-yl group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of: C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

14. (Currently Amended) The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a8}CO-O-$ , wherein  $R^{a8}$  represents a group of the formula (X):



wherein  $n_4$  represents an integer of 1 to 3,

$R^{aN30}$  represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent or
- 4) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent, and


$R^{aN31}$  represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,
- 5) a C<sub>6</sub> to C<sub>14</sub> aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent; or  
a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:  
C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

15. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a9</sup>CO-O-, wherein R<sup>a9</sup> represents a group of the formula (XI):



wherein n<sub>4</sub> represents an integer of 1 to 3, and

R<sup>aN32</sup> represents

- 1) a hydrogen atom,
- 2) a C<sub>1</sub> to C<sub>6</sub> alkyl group which may have a substituent,
- 3) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 4) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 5) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 6) a pyridyl group which may have a substituent or


7) a tetrahydropyranyl group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:

$C_1$ - $C_6$  alkyl group, phenyl group, halogen, hydroxyl group,  $C_1$ - $C_6$  alkoxy group, thiol group,  $C_1$ - $C_6$  alkylthio group, nitro group, nitroso group, cyano group,  $C_1$ - $C_6$  alkoxy carbonyl group, amino group, mono ( $C_1$ - $C_6$  alkyl) amino group, di ( $C_1$ - $C_6$  alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

16. (Currently Amended) The compound according to claim 2, wherein  $R^{7a}$  and/or  $R^{21a}$  represent  $R^{a10}CO-O-$ , wherein  $R^{a10}$  represents a group of the formula (XII):



wherein  $m_1$ ,  $m_2$ ,  $m_3$  and  $m_4$ , the same or differently, represent 0 or 1,

$n_4$  represents an integer of 1 to 3, and

$R^{aN33}$  represents


- 1) a hydrogen atom,
- 2) a  $C_1$  to  $C_6$  alkyl group which may have a substituent,
- 3) an unsaturated  $C_2$  to  $C_{10}$  alkyl group which may have a substituent,
- 4) a  $C_6$  to  $C_{14}$  aryl group which may have a substituent,

- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C<sub>7</sub> to C<sub>10</sub> aralkyl group which may have a substituent,
- 7) a C<sub>3</sub> to C<sub>8</sub> cycloalkyl group which may have a substituent,
- 8) a C<sub>4</sub> to C<sub>9</sub> cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or

a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:  
C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

17. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a11</sup>CO-O-, wherein R<sup>a11</sup> represents a group of the formula (XIII):




wherein m<sub>5</sub> represents an integer of 1 to 3, and n<sub>5</sub> represents 2 or 3; or a pharmacologically acceptable salt thereof, and


wherein said substituents are each independently selected from the group consisting of:

C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

18. (Currently Amended) The compound according to claim 2, wherein R<sup>7a</sup> and/or R<sup>21a</sup> represent R<sup>a12</sup>CO-O-, wherein R<sup>a12</sup> represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;

or a pharmacologically acceptable salt thereof, and

wherein said substituents are each independently selected from the group consisting of:  
C<sub>1</sub>-C<sub>6</sub> alkyl group, phenyl group, halogen, hydroxyl group, C<sub>1</sub>-C<sub>6</sub> alkoxy group, thiol group, C<sub>1</sub>-C<sub>6</sub> alkylthio group, nitro group, nitroso group, cyano group, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl group, amino group, mono (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, di (C<sub>1</sub>-C<sub>6</sub> alkyl) amino group, pyrrolidyl group, piperadyl group, piperidyl group and pyridyl group.

19. (Previously Presented) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide,  
(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide and  
(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricos-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof.

20. (Cancelled)

21. (Previously Presented) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Cancelled)